Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
J Pediatr ; 193: 204-210, 2018 02.
Article in English | MEDLINE | ID: mdl-29212620

ABSTRACT

OBJECTIVE: To evaluate the status of congenital diaphragmatic hernia (CDH) management in France and to assess predictors of adverse outcomes. STUDY DESIGN: We reviewed the first-year outcome of all cases of CDH reported to the French National Register in 2011. RESULTS: A total of 158 cases were included. Of these, 83% (131) were prenatally diagnosed, with a mortality rate of 39% (44 of 112) for live born infants with a known outcome at hospital discharge. Mortality increased to 47% (60 of 128) including those with termination of pregnancy and fetal loss. This contrasts with the 7% (2 of 27) mortality rate of the patients diagnosed postnatally (P = .002). Mortality worsened with 1 prenatal marker of CDH severity (OR 3.38 [1.30-8.83] P = .013) and worsened further with 2 markers (OR 20.64 [5.29-80.62] P < .001). Classic postnatal risk factors of mortality such as side of hernia (nonleft P = .001), prematurity (P < .001), low birth weight (P = .002), and size of the defect (P < .001) were confirmed. Of the 141 live births (114 prenatal and 27 postnatal diagnosis) with known outcomes, 93 (67%) survived to hospital discharge, 68 (60%) with a prenatal diagnosis and 25 (93%) with a postnatal diagnosis. The median time to hospital discharge was 34 days (IQR, 19.25-62). Of these survivors, 71 (76%) were followed up for 1 year. CONCLUSIONS: Despite advances in management of CDH, mortality was high and associated with prenatal risk factors. Postnatally, severe persistent pulmonary hypertension was difficult to predict and presented persistent challenges in management.


Subject(s)
Hernias, Diaphragmatic, Congenital/mortality , Female , France , Hernias, Diaphragmatic, Congenital/therapy , Humans , Infant , Infant Mortality , Infant, Newborn , Male , Pregnancy , Prenatal Care , Prenatal Diagnosis , Prospective Studies , Registries , Risk Factors , Survival Rate , Treatment Outcome
2.
J Pediatr ; 157(4): 623-9, 629.e1, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20553844

ABSTRACT

OBJECTIVE: To test the hypothesis that predisposition to childhood herpes simplex virus (HSV) type 1 encephalitis (HSE) may be determined in part by human genetic factors. STUDY DESIGN: A genetic epidemiologic survey of childhood HSE (onset at age 3 months to 15 years) over a 20-year period (1985-2004) was conducted throughout France (comprising 29 university hospital neuropediatric centers). A total of 85 children fulfilled the diagnostic criteria for inclusion. Family and personal histories were obtained by face-to-face interview for 51 patients. RESULTS: No familial cases of HSE were identified in our survey; however, a high proportion (20%) of the children interviewed had a relevant family history: parental consanguinity (12% of patients), early-onset herpetic keratitis in a first-degree relative (6%), or both (2%). The narrow window of high susceptibility to HSE before age 3 years (62% of patients) further indicates that predisposition to HSE is tightly age-dependent. CONCLUSIONS: This survey suggests that childhood HSE, although sporadic, may result from Mendelian predisposition (from autosomal recessive susceptibility in particular), at least in some children. There likely is incomplete penetrance, however, which may reflect, at least in part, the impact of age at the time of HSV-1 infection.


Subject(s)
Encephalitis, Herpes Simplex/genetics , Encephalitis, Herpes Simplex/virology , Genetic Variation , Toll-Like Receptor 3/genetics , Acyclovir/therapeutic use , Adolescent , Age Factors , Age of Onset , Antiviral Agents/therapeutic use , Child , Child, Preschool , Encephalitis, Herpes Simplex/drug therapy , Female , Genetic Predisposition to Disease , Genetic Variation/genetics , Humans , Infant , Male , Risk Factors , Simplexvirus , Young Adult
3.
Trials ; 20(1): 115, 2019 Feb 11.
Article in English | MEDLINE | ID: mdl-30744679

ABSTRACT

BACKGROUND: Catheter-related bacteremia (CRB) is the most frequent nosocomial infection in neonatal intensive care unit (NICU) patients, especially in very low-birth-weight infants. Administration of injectable drugs in premature newborn infants has many particularities and several types of infusion incidents have been reported. The Edelvaiss® Multiline NEO device is a novel multi-lumen access infusion device adapted to the specificities of infusion in neonatology. This multicenter, randomized, controlled study was therefore designed to determine whether or not Edelvaiss® Multiline NEO reduces the risk of CRB in preterm newborn infants in an NICU. METHODS/DESIGN: This is a multicenter, randomized, controlled trial, using a cluster-randomized crossover design. Four investigator centers (four clusters) will participate in the study and will be randomized into two groups, corresponding to two different sequences (either the Edelvaiss® Multiline NEO or standard infusion system sequence, then vice versa). A total of 280 patients will be recruited. Infants will be enrolled in the study at the time of placing a single-lumen central venous catheter. Three visits recording specific data are planned in the study protocol. The primary outcome measure is the incidence density (ID) of CRB. For each patient, the total number of catheters and CRB incidents as well as the duration of stay in the NICU will be computed and considered for analysis. DISCUSSION: The study will provide high-quality evidence to determine whether the Multiline NEO device reduces the risk of CRB in preterm newborns in NICUs or not. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02633124 . Registered on 7 December 2015.


Subject(s)
Bacteremia/prevention & control , Catheter-Related Infections/prevention & control , Catheterization, Central Venous/instrumentation , Catheters, Indwelling/microbiology , Central Venous Catheters/microbiology , Cross Infection/prevention & control , Infant, Extremely Premature , Bacteremia/diagnosis , Bacteremia/microbiology , Catheter-Related Infections/diagnosis , Catheter-Related Infections/microbiology , Catheterization, Central Venous/adverse effects , Cross Infection/diagnosis , Cross Infection/microbiology , Cross-Over Studies , Equipment Design , Female , Gestational Age , Humans , Infant, Newborn , Infusions, Intravenous , Intensive Care Units, Neonatal , Male , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome
4.
Intensive Care Med ; 33(7): 1168-1172, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17503017

ABSTRACT

OBJECTIVE: The present study evaluated the usefulness of a real-time polymerase chain reaction (rtPCR) assay for the detection of Neisseria meningitidis (Nm) and genogrouping on skin lesion biopsies in patients with purpura fulminans (PF). DESIGN: Retrospective single-centre study. SETTING: Adult and paediatric intensive care units at the University Hospital of Rouen. PATIENTS: All patients admitted between January 2000 and January 2006, with a final diagnosis of PF and for which a skin biopsy and blood cultures were performed, were included. INTERVENTIONS: Skin biopsy and blood cultures were used for culture and rtPCR. MEASUREMENTS AND MAIN RESULTS: Thirty-four patients fulfilled the criteria (27 children and 7 adults). Nm rtPCR performed on skin biopsy was positive in 100% (34/34) of cases, compared with only 14.7% (5/34) for skin culture (p=0.0001). rtPCR genogrouping on skin biopsy was positive in 58.8% (20/34) of the cases compared with 14.7% (5/34) for skin culture (p=0.0013). For patients (n=17) in whom rtPCR was performed both on blood and skin biopsy, skin biopsy gave a significantly higher rate of Nm detection [100% (17/17) vs. 58.8% (10/17); p=0.023] and genogroup characterisation [76.5% (13/17) vs. 35.3% (6/17); p=0.045] than blood. We encountered no specimen with culture-positive and rtPCR-negative results (negative predictive value of rtPCR 100%). CONCLUSION: In suspected PF cases, skin biopsy is more reliable to identify Nm and its genogroup than blood or, probably, CSF, especially when PCR methods are used. This could help the implementation of public health interventions, especially concerning a vaccination policy.


Subject(s)
DNA, Bacterial/isolation & purification , IgA Vasculitis/microbiology , Neisseria meningitidis/isolation & purification , Polymerase Chain Reaction/methods , Skin/microbiology , Adult , Biopsy , Blood/microbiology , Child , Humans , Intensive Care Units , Intensive Care Units, Pediatric , Neisseria meningitidis/genetics , Retrospective Studies , Skin/chemistry
5.
Pediatr Infect Dis J ; 25(12): 1186-8, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17133169

ABSTRACT

Twenty children with proven (n = 12) or probable (n = 8) invasive fungal infections received caspofungin treatment either as first-line (n = 7) or as salvage (n = 13) therapy and as monotherapy (n = 5) or in combination (n = 15). Eleven had aspergillosis, 7 had candidiasis, and 2 had Rhodotorula infections. Caspofungin was well tolerated. Nine patients experienced 11 drug-related adverse events, none were severe, and none led to drug discontinuation. Caspofungin as a first-line treatment was successful in 5 of the 7 children (these 5 patients survived the infectious episode, with a follow-up of 147 days), and salvage therapy rescued 8 of 13 children, but only 5 of them survived.


Subject(s)
Antifungal Agents/adverse effects , Antifungal Agents/therapeutic use , Mycoses/drug therapy , Peptides, Cyclic/adverse effects , Peptides, Cyclic/therapeutic use , Adolescent , Aspergillus/isolation & purification , Candida/isolation & purification , Caspofungin , Child , Child, Preschool , Drug Therapy, Combination , Echinocandins , Female , Humans , Infant , Lipopeptides , Male , Mycoses/microbiology , Retrospective Studies , Rhodotorula/isolation & purification , Salvage Therapy
6.
JAMA Pediatr ; 170(4): 365-72, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26928567

ABSTRACT

IMPORTANCE: Although immature neonate survival has improved, there is an increased risk of developing bronchopulmonary dysplasia, leading to significant respiratory morbidity. Measures to reduce bronchopulmonary dysplasia are not always effective or have important adverse effects. OBJECTIVE: To evaluate the effect of late surfactant administration in infants with prolonged respiratory distress on ventilation duration, respiratory outcome at 36 weeks' postmenstrual age, and at 1 year postnatal age. DESIGN, SETTING, AND PARTICIPANTS: Double-blind randomized clinical trial at 13 level III French perinatal centers. Participants included 118 neonates at less than 33 weeks' gestation who still required mechanical ventilation on day 14 (SD, 2) with fraction of inspired oxygen of more than 0.30. All survivors were eligible for follow-up. We performed an intent-to-treat analysis. INTERVENTIONS: Infants received 200 mg/kg of poractant alfa (surfactant) or air after randomization. At 1 year, after parents' interview, infants underwent physical examination by pediatricians not aware of the randomization. MAIN OUTCOMES AND MEASURES: The duration of ventilation was the primary outcome. The combined outcome of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual age and respiratory morbidity at 1 year of age were the main secondary outcome measures. RESULTS: Of the 118 infants who participated in the study, 65 (55%) were male. Fraction of inspired oxygen requirements dropped after surfactant, but not air, for up to 24 hours after instillation (0.36 [0.11] vs 0.43 [0.18]; P < .005). Severe bronchopulmonary dysplasia/death rates at 36 weeks' postmenstrual age were similar (27.1% vs 35.6%; P = .32). Less surfactant-treated infants needed rehospitalization for respiratory problems after discharge (28.3% vs 51.1%; P = .03); 39.5% vs 50% needed respiratory physical therapy (P = .35). No difference was observed for weight (7.8 [1.2] kg vs 7.6 [1.1] kg), height (69 [5] cm vs 69 [3] cm), and head circumference (44.4 [1.7] cm vs 44.2 [1.7] cm) measured at follow-up, nor for neurodevelopment outcome. CONCLUSIONS AND RELEVANCE: Late surfactant administration did not alter the early course of bronchopulmonary dysplasia. However, surfactant-treated infants had reduced respiratory morbidity prior to 1 year of age. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01039285.


Subject(s)
Biological Products/administration & dosage , Phospholipids/administration & dosage , Pulmonary Surfactants/administration & dosage , Respiratory Distress Syndrome, Newborn/drug therapy , Bronchopulmonary Dysplasia/physiopathology , Double-Blind Method , Female , Gestational Age , Humans , Infant , Infant, Extremely Premature , Infant, Newborn , Lung/drug effects , Lung/physiopathology , Male , Respiration, Artificial/methods , Respiratory Distress Syndrome, Newborn/physiopathology , Time Factors
8.
J Child Neurol ; 28(6): 787-90, 2013 Jun.
Article in English | MEDLINE | ID: mdl-22791546

ABSTRACT

The authors present a child affected with diaphragmatic paralysis in the early neonatal period. Although no electroneuromyographic abnormalities were reported, the patient developed dramatic motor and respiratory impairment with impossibility to wean from mechanical ventilation. Repeated electroneuromyographic study at age 4 months revealed severe neurogenic changes and sensory nerve abnormalities with more preserved nerve conduction velocities. Genetic studies identified 2 mutations in the gene IGHMBP2. These results support the consideration of this entity as a form of sensory-motor rapidly progressive polyneuropathy rather than a primary anterior horn disease (IGHMBP2-related neuropathy). A review of the series of mutated patients in the French National Database gives new insights of the incidence of this disease in France.


Subject(s)
DNA Mutational Analysis , DNA-Binding Proteins/genetics , Muscular Atrophy, Spinal/genetics , Respiratory Distress Syndrome, Newborn/genetics , Respiratory Paralysis/genetics , Transcription Factors/genetics , Cross-Sectional Studies , Diagnosis, Differential , Electromyography , Fatal Outcome , Humans , Infant , Infant, Newborn , Male , Muscular Atrophy, Spinal/diagnosis , Muscular Atrophy, Spinal/therapy , Neurologic Examination , Phenotype , Respiratory Distress Syndrome, Newborn/diagnosis , Respiratory Distress Syndrome, Newborn/therapy , Respiratory Paralysis/diagnosis , Respiratory Paralysis/epidemiology , Respiratory Paralysis/therapy , Ventilator Weaning
9.
Pediatrics ; 119(4): e860-5, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17339385

ABSTRACT

OBJECTIVE: In a previous multicenter, randomized trial, elective use of high-frequency oscillatory ventilation was compared with the use of conventional ventilation in the management of respiratory distress syndrome in preterm infants <30 weeks. No difference in terms of respiratory outcome was observed, but concerns were raised about an increased rate of severe intraventricular hemorrhage in the high-frequency ventilation group. To evaluate outcome, a follow-up study was conducted until a corrected age of 2 years. We report the results concerning neuromotor outcome. METHODS: Outcome was able to be evaluated in 192 of the 212 infants who survived until discharge from the neonatal unit: 97 of 105 infants of the high-frequency group and 95 of 104 infants of the conventional ventilation group. RESULTS: In the infants reviewed, mean birth weight and gestational age were similar in the 2 ventilation groups. As in the overall study population, the following differences were observed between the high-frequency ventilation group and the conventional ventilation group: lower 5-minute Apgar score, fewer surfactant instillations, and a higher incidence of severe intraventricular hemorrhage. At a corrected age of 2 years, 93 of the 97 infants of the high-frequency group and 79 of the 95 infants of the conventional ventilation group did not present any neuromotor disability, whereas 4 infants of the high-frequency group and 16 infants of the conventional ventilation group had cerebral palsy. CONCLUSIONS: Contrary to our initial concern about the increased rate of severe intraventricular hemorrhage in the high-frequency ventilation group, these data suggest that early use of high-frequency ventilation, compared with conventional ventilation, may be associated with a better neuromotor outcome. Because of the small number of patients studied and the absence of any explanation for this finding, we can conclude only that high-frequency oscillatory ventilation is not associated with a poorer neuromotor outcome.


Subject(s)
High-Frequency Ventilation/adverse effects , Infant, Premature , Infant, Very Low Birth Weight , Intermittent Positive-Pressure Ventilation/adverse effects , Psychomotor Disorders/epidemiology , Respiratory Distress Syndrome, Newborn/therapy , Child, Preschool , Female , Follow-Up Studies , High-Frequency Ventilation/methods , Humans , Infant , Infant, Newborn , Intermittent Positive-Pressure Ventilation/methods , Logistic Models , Male , Multivariate Analysis , Odds Ratio , Probability , Psychomotor Disorders/etiology , Respiratory Distress Syndrome, Newborn/diagnosis , Respiratory Distress Syndrome, Newborn/mortality , Risk Assessment , Severity of Illness Index , Survival Rate , Time Factors
10.
Pediatr Radiol ; 36(8): 870-3, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16767400

ABSTRACT

We report a rare example of catastrophic antiphospholipid syndrome (CAPS) in a young child. A 3-year-old girl with no previous medical history presented with extensive and recurrent thromboses. The diagnosis of CAPS was based on the occurrence of cardiopulmonary embolism in the child with a high titre of autoantibodies directed against phospholipids and beta-2-glycoprotein 1. In spite of a relatively rapid diagnosis and multiple treatments, the outcome was unfavourable. Multimodality imaging, including both ultrasonography and spiral CT, allowed close follow-up of the thromboses.


Subject(s)
Antiphospholipid Syndrome/diagnosis , Pulmonary Embolism/diagnosis , Thromboembolism/diagnosis , Antiphospholipid Syndrome/complications , Catastrophic Illness , Child, Preschool , Fatal Outcome , Female , Humans , Pulmonary Embolism/etiology , Pulmonary Embolism/therapy , Thromboembolism/etiology , Thromboembolism/therapy
SELECTION OF CITATIONS
SEARCH DETAIL